Obesity-related insulin resistance is driven by low-grade chronic inflammation of metabolic tissues. In the liver, nonalcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood. We found that the liver accumulates pathogenic CD8 + T cell subsets, which control hepatic insulin sensitivity and gluconeogenesis during diet-induced obesity in mice. In a cohort of human patients, CD8
INTRODUCTION
Obesity is a major risk factor for the development of type 2 diabetes and its precursor, insulin resistance (IR). Multiple factors contribute to obesity-induced IR, but low-grade chronic inflammation of metabolic tissues is one central factor in its development (1, 2) . This inflammation is driven by both innate and adaptive immune cells. During obesity, T cell composition in various tissues is altered to favor inflammatory subsets that promote IR. In particular, CD4 + and CD8 + T cells are pivotal in orchestrating visceral adipose tissue (VAT) inflammation and metabolic disease during obesity (3, 4) . In addition to VAT, the liver is a key site that becomes altered during obesity (5) . Nonalcoholic fatty liver disease (NAFLD) and its progressed inflammatory state [nonalcoholic steatohepatitis (NASH)] are manifestations of metabolic syndrome in the liver and have emerged as leading causes of abnormal liver function (6) . NAFLD is characterized by increased intrahepatic fat content, which is tightly associated with IR (7) . NAFLD and NASH also predispose to liver failure and liver cancer and are among the leading causes of organ transplantation in North America, with no approved pharmacological therapies (8) .
The underlying mechanisms linking fatty liver, inflammation, and IR are largely unknown. Human NAFLD has been associated with enhanced proinflammatory cytokine markers, including tumor necrosis factor- (TNF), interleukin-1 (IL-1), and IL-6 (9, 10) . Early studies have focused primarily on cells of innate immunity as drivers of the inflammatory and morphological changes that arise in fatty livers. For example, NAFLD is characterized by increased hepatic myeloid cells and aberrant release of T helper 1 (T H 1)-polarizing inflammatory cytokines (11) . Ablation of Kupffer cells improves hepatic steatosis, inflammation, and metabolic disease (12, 13) . However, few studies have examined the effects of diet-induced obesity (DIO) on adaptive immune cell populations within the liver. In mice, NASH promotes an increase in hepatic CD8 + /CD4 + T cell ratio, dictated by dendritic cell function (14) . In NASH, there is an imbalance between excess T H 1-derived cytokines, such as interferon  (IFN), and a deficiency in T H 2-derived cytokines, including IL-4, IL-5, and IL-13 (15) . Consistently, in obese pediatric patients, there is a positive correlation between elevated numbers of circulating IFN-expressing CD4 + T cells and clinical signs of NAFLD (16) . Recently, intrahepatic CD4 + and CD8 + T cells have been implicated in modulating the transition between NASH and liver cancer (17) (18) (19) , but whether these cells control hepatic IR, whole-body glucose intolerance, and overall metabolic syndrome is unknown. Furthermore, the mechanisms and immunological signals that support liver inflammation and maintain pathogenic effector immune cell populations during obesity are poorly understood.
Here, we show that high-fat diet (HFD) feeding in a murine model of obesity-related IR and NAFLD induces the expansion of pathogenic intrahepatic CD8
+ T cells that promote metabolic disease. Intrahepatic CD8 + T cell increase is accompanied by an obesity-induced hepatic type I interferon (IFN-I) response that fuels their accumulation and pathological function. In human patients, the frequency of intrahepatic CD8 + T cells positively correlates to glycated hemoglobin (HbA1c) levels. Moreover, intrahepatic CD8 + T cells and the presence of intrahepatic IFN-I expression are associated with NAFLD disease activity. Thus, DIO promotes an IFN-I response that drives metabolically activated intrahepatic T cell pathogenicity, resulting in NAFLD progression and glucose dysregulation.
RESULTS

Obesity induces a proinflammatory shift in intrahepatic T cell populations
To address the effects of obesity on hepatic immune cell populations, we first investigated whether adaptive immune cells within the liver are altered by HFD (60% kcal fat) feeding in C57BL/6 [wild-type (WT)] mice for 16 weeks. Compared with normal chow diet (NCD)-fed mice, HFD-fed mice showed worsened glucose tolerance test (GTT), insulin tolerance test (ITT), and pyruvate tolerance test (PTT) (fig. S1A); increased content of triglycerides in the liver (fig. S1B); and a substantial increase in the number of total CD3 + T cells in the liver (Fig. 1A) . Within the CD3 + T cell compartment, HFD-fed mice displayed increased frequency of intrahepatic CD8 + T cells, a reduction in the frequency of CD4 + T cells, and no changes in the frequencies of  TCR + (T cell receptor-positive) T cell or CD4 + Foxp3 + T regulatory (T reg ) cells (Fig. 1B, left) . However, quantification of cell number per gram of liver tissue revealed that HFD feeding increased all these intrahepatic T cell subsets, with the greatest increase observed in the CD8 + T cell compartment (Fig. 1B, right) . HFD-fed mice showed a decrease in hepatic CD1d-restricted invariant natural killer (NK) T cells, as indicated by -galactosylceramide-loaded CD1d tetramer staining ( fig. S1C ), whereas the frequency and number of NK cells increased ( fig. S1D ). No differences in the frequency and number of splenic T cell subsets were found between NCD-and HFD-fed mice (fig. S1, E and F). Compared with NCD, HFD feeding markedly increased the frequency and cell number of intrahepatic CD8 + CD62L − CD44 + T effector memory cells, whereas no changes in intrahepatic CD4 + CD62L − CD44 + T effector memory cells were detected (Fig. 1C) . In the spleen, we found no differences in the expression of activation markers in CD8 + and CD4 + T cells between NCD-and HFD-fed mice ( fig. S1G ). Additionally, intrahepatic CD8 + T cells in HFD-fed mice were mainly CD8 + T cells, and no differences in the proportion of CD8 + or CD8 + cells were found compared with NCD-fed mice ( fig. S1H ). We next assessed whether T cell changes occurred in the liver specific to HFD-induced obesity or whether they occur in another model of obesity, the ob/ob mice, which are genetically obese on NCD. Similar to HFD-fed mice, ob/ob mice showed increased frequency and number of intrahepatic CD8 + T cells, and reduced frequency of CD4 + T cells, compared with WT controls (fig. S1, I and J). Differences in T cell subpopulations in the spleen were not observed between ob/ob and WT mice ( fig. S1K ).
Given the notable increases in intrahepatic T cells in the HFD model, we investigated mechanisms of increased T cell numbers in the liver. We assessed T cell proliferation by staining for Ki-67 and through the use of 5-ethynyl-2′-deoxyuridine (EdU) uptake. Intrahepatic CD8 + and CD4 + T cell subsets in HFD-fed mice had increased percentages of Ki-67 + and EdU + cells, compared with NCD-fed controls (Fig. 1, D and E), suggesting that HFD feeding promotes the proliferation of intrahepatic T cells.
To assess the potential of intrahepatic T cell subsets to produce proinflammatory cytokines in response to HFD feeding, we determined their intracellular expression of IFN and TNF. Compared with NCDfed controls, mice fed a HFD for 16 S2D ) and intracellular expression of IFN during HFD feeding ( fig. S2E ), suggesting that there may be some systemic activation of CD4 + T cells during HFD feeding, although its changes are relatively small compared with the marked T cell inflammatory changes in the liver. No differences in splenic TNF + CD8 + T cells were found ( fig. S2F ). To determine the timing of hepatic T cell infiltration over the course of HFD feeding, we analyzed the T cell populations in mice fed an NCD or HFD for shorter duration (10 weeks) and longer duration (32 weeks (3, 4) . Thus, we next investigated whether similar features are characteristic of intrahepatic T cells during DIO. Analysis of TCRV expression on total intrahepatic or splenic CD8 + and CD4 + T cells revealed unremarkable differences between HFD-and NCD-fed mice ( fig. S4, A and B) . These results suggest that expanded T cells are of unbiased repertoires and may potentially accumulate through bystander expansion, although a central role for antigen-specific immunity driving T cell accumulation cannot be entirely ruled out. Collectively, our results demonstrate a proinflammatory shift in various T cell subsets in the livers of HFD-fed mice, with a large increase in the frequency and number of IFN-and TNF-producing CD8 + T cells. To determine whether there is an association between intrahepatic T cells and glucose dysregulation in humans, we assessed the frequency of intrahepatic immune cells in a cohort of human liver donor tissues (20) . A mixed population of liver donors with varying degrees of body mass index (BMI), fatty liver changes (without NASH), and glucose dysregulation were analyzed for intrahepatic immune cell subsets by flow cytometry and correlated to BMI and HbA1c. Of all immune cell populations analyzed, only intrahepatic CD8 + T cell populations significantly positively correlated with HbA1c levels (Fig. 1H) , although there was no significant correlation between CD8 + T cells and BMI (Fig. 1I) . CD4 + T cells ( HbA1c levels ( fig. S5, A and B) . These findings suggest that intrahepatic CD8 + T cells are associated with glucose dysregulation in this cohort of humans, supporting a potential pathogenic role of intrahepatic CD8 + T cells in human glucose homeostasis.
Intrahepatic CD8 + T cells drive hepatic IR and metabolic disease
We next investigated whether intrahepatic CD8 + T cells play a role in the pathogenesis of fatty liver and hepatic IR during DIO because hepatic insulin signaling is required for normal whole-body glucose homeostasis (1). Compared with WT controls, CD8-deficient (CD8 −/− ) mice fed a HFD for 16 weeks displayed only marginal improvements in fatty liver changes, as demonstrated by a trend to decreased liver triglyceride content and overall subtle changes in macrovesicular steatosis observed on hematoxylin and eosin (H&E) sections ( Fig. 2A) . Despite similar body weight (Fig. 2B ), HFD-fed CD8 −/− mice had improved systemic insulin sensitivity as shown by a GTT and ITT, compared with WT controls ( fig. S6A ). Because increased hepatic IR leads to enhanced hepatic glucose production through activation of gluconeogenic pathways, PTTs were performed to determine the degree of hepatic IR and gluconeogenesis activity in HFD-fed CD8 −/− mice. HFD-fed CD8 −/− mice displayed improved overall pyruvate tolerance, compared with WT HFD-fed mice (Fig. 2B ). HFD-fed CD8 −/− mice also showed reduced mRNA expression of genes that encode the key gluconeogenic enzymes G6pc and Pepck1 in liver lysates (Fig. 2C) , suggesting that CD8 + T cells play a role in regulating hepatic glucose production by modulating hepatocyte gluconeogenesis. No differences in gene expression of the lipogenic genes Srebp1 and Ppar were detected, reflecting the marginal changes observed in histology ( Next, to determine the direct effect of intrahepatic CD8 + T cells on whole-body glucose homeostasis and hepatic glucose production, we adoptively transferred purified liver or splenic CD8 + T cells from HFD-fed WT donor mice into HFD-fed CD8 −/− recipient mice and performed GTT, ITT, and PTT. Transfer of splenic CD8 + T cells induced marginal effects on the metabolic parameters measured compared with phosphate-buffered saline (PBS) alone, whereas transfer of isolated liver CD8 + T cells induced a marked worsening of glucose metabolic parameters (Fig. 2D ). To further confirm our insulin tolerance studies, we measured the protein levels of total and phosphorylated Akt (pAkt) in liver tissue of adoptively transferred mice. Compared with PBS-treated controls, both liver CD8 + and splenic CD8 + T cell transfers impaired insulin signaling in liver tissue, as determined by lower pAkt/Akt ratios, although liver CD8 + T cell transfers had a greater effect (Fig. 2E) . A greater percentage of CD8 + T cells reconstituted recipient liver tissue, as opposed to VAT or spleen, in liver CD8 + T cell transfers (Fig. 2F ). Liver CD8 + T cell transfers displayed a greater proportion of activated CD62L − CD44 + T effector memory subsets, which may be one reason for their enhanced pathogenicity compared with splenic CD8 + T cell transfers (Fig. 2F ). Collectively, these data suggest that hepatic CD8 + T cells are a unique, highly pathogenic, tissue-specific immune mediator of obesity-related glucose dysregulation. Moreover, the pathogenicity of hepatic CD8 + T cells is, in part, linked to modulation of hepatocyte gluconeogenesis, which is a process augmented by hepatic IR. Given the large increases in proinflammatory cytokine production observed in these cells, such processes may potentially occur through the release of IFN and TNF, which impair insulin receptor signaling in several tissues (1, 21) . Thus, we treated primary hepatocytes with IFN, TNF, or both to investigate their effects on insulin signaling. Treatment of hepatocytes with IFN, TNF, or both reduced pAkt/Akt protein ratios compared with untreated cells (Fig. 2G) . The results support the notion that typical inflammatory cytokines produced by CD8 + T cells impair downstream insulin signaling in the liver.
HFD feeding induces an IFN-I response in the liver that promotes IR
Given that intrahepatic CD8 + T cells show important pathological functions on glucose homeostasis, we next investigated potential immunological mechanisms governing the activation and persistence of proinflammatory intrahepatic T cells observed in HFD-fed mice. IFN-I responses are critical for the survival, memory, effector differentiation, proliferation, and cytolytic activity of T cells during various settings, including infection (22) . Driven by IFN and IFN, IFN-I responses are transcriptionally regulated by interferon regulatory factors (IRFs) and are induced after pathogen recognition by pattern recognition receptors (23) . Secreted signal through the interferon  receptor (IFNR) to induce the expression of interferon stimulatory genes (ISGs). We examined whether HFD feeding results in an IFN-I response that fuels the activation of intrahepatic T cells during DIO. Compared with NCD type I interferons controls, HFD-fed mice showed enhanced hepatic expression of IRF3 and IRF7, key transcription factors involved in the regulation of IFN-I responses, as well as several ISGs, including Isg15, Ifit1, and Ifi44 (Fig. 3A, left) . Livers from HFD-fed mice also had increased expression of IFNR in a number of immune cells, including CD8 T cells ( fig. S6F ), as well as higher contents of IFN protein (Fig. 3A, right) . To examine the relative contribution of several intrahepatic immune cells to the increased response to IFN-I, we determined the expression of ISGs in CD8 controls (Fig. 3C, left) . This finding was consistent with reduced liver weight (Fig. 3C, middle) , triglyceride content (Fig. 3C, right) , and lipid content observed by oil red O staining ( fig. S7A ) in IFNR1 −/− HFD-fed mice, whereas no differences in adipose tissue weight (Fig. 3D , left) or total body weight (Fig. 3D, right) were found. Compared with WT HFD-fed control mice, HFD-fed IFNR1 −/− mice were protected from DIO-related IR, as determined by improved GTTs, ITTs, and PTTs (Fig. 3E) , and reduced plasma fasting glucose and insulin levels (Fig. 3F) . This protection was dependent on HFD feeding because NCD-fed IFNR1 −/− mice displayed no differences in the metabolic tests performed, compared with WT controls (fig. S7, B to D) . These data suggest that factors present in HFD or obese settings promote pathogenic IFN-I responses. To further confirm IR in the liver, we measured protein levels of total Akt and pAkt after insulin challenge, and consistent with our findings, IFNR1 −/− HFD-fed mice displayed higher levels of pAkt/Akt ratios compared with WT HFD-fed controls (Fig. 3G) .
We then investigated whether intrahepatic T cells relied on IFN-I cytokines for their activation and accumulation. IFNR1 −/− HFD-fed mice exhibited lower total intrahepatic CD8 + and CD4 + T cells (Fig. 3H) , with no significant differences observed in the spleen ( fig. S7E ). Remarkably, the frequency and total number of CD62L − CD44 + T effector memory CD8 + and CD4 + T cell subsets were strikingly decreased in IFNR1 −/− HFD-fed mice, similar to levels observed in NCD-fed mice (Figs. 1C and 3H ). Ki-67 + , CD8 + , and CD4 + intrahepatic T cells were also reduced in IFNR1 −/− HFD-fed mice (Fig. 3I) ,
suggesting that IFN-I promotes the proliferation of intrahepatic T cells. Upon stimulation, intrahepatic T cells from IFNR1
−/− HFD-fed mice displayed marked decreased frequencies and cell numbers of IFN + CD8 + and CD4 + cells (Fig. 3J) . Although no differences were detected in the percentages of TNF + CD8 + and CD4 + T cells, IFNR1 −/− HFD-fed mice showed a decrease in the number of TNF + CD8 + intrahepatic T cells (Fig. 3K) S7H) were also found to be marginally reduced in IFNR1 −/− HFD-fed mice. Overall, these findings suggest that IFN-I responses fuel the proliferation and activation of intrahepatic T cells, leading to an increased release of pathogenic inflammatory cytokines during DIO.
Because we identified IFN-I as a dominant central process governing glucose homeostasis in knockout mice, we next assessed whether reducing IFN-I through an IFNR1-blocking antibody after established metabolic disease could have therapeutic potential. We treated mice fed a HFD for 10 weeks with either anti-IFNR1 antibody (400 g per week) or immunoglobulin G (IgG) control for 5 weeks and performed metabolic testing. Despite no changes in body weight, mice receiving anti-IFNR1-blocking antibody showed improved glucose tolerance, insulin sensitivity, and pyruvate tolerance at the end of the treatment course (Fig. 4A) . IFNR1 blocking was confirmed by flow cytometry, and improved disease correlated with reduced total intrahepatic CD8 + and CD4 + T cells and decreases in T effector memory populations (Fig. 4B) . Together, these data suggest that IFN-I responses represent a critical immunological mechanism for the expansion and proliferation of activated proinflammatory intrahepatic T cells observed during HFD feeding.
Given that IFN-I responses can control intrahepatic immune populations and glucose metabolism, we next sought out possible sources of IFN-I production in DIO. Obesity-associated changes in the gut microbiota control inflammation and IR partly through increased gutderived bacterial products, such as lipopolysaccharide (LPS) and unmethylated CpG DNA (24, 25) , which have been also shown to regulate the progression of NAFLD (26) . Because the liver receives direct drainage of blood containing food and bacterial antigens from the gut, we questioned whether such products could induce hepatic IFN-I production. We treated primary hepatocytes isolated from WT mice with LPS [toll-like receptor 4 (TLR4) agonist] or unmethylated CpG/ oligodeoxynucleotide (ODN) 2395 (TLR9 agonist). Compared with untreated controls, both LPS and CpG ODN increased the expression of IRF3, whereas CpG ODN treatment resulted in higher expression of IRF7 (fig. S8A ). These results suggest that such bacterial products within liver tissue may be one potential inducer of the IFN-I responses. Saturated free fatty acids (FFAs) have also been identified to contribute to the development of fatty liver disease in TLR2-and TLR4-dependent manners (27) . Although IRF7 showed a trend to increased expression with high-dose palmitate, overall, we found no significant differences in IRF3 and IRF7 gene expression in hepatocytes stimulated with palmitate ( fig. S8B) .
To identify whether increased liver IFN-I responses and intrahepatic T cell inflammation during DIO are driven by intestinal bacterial components, we depleted WT HFD-fed mice of commensal bacteria by oral administration of broad-spectrum antibiotics (28) . . S8I ), compared with IFNR1 −/− controls. This finding is consistent with the notion that IFN-I responses mechanistically promote some of the detrimental effects of bacteria on glucose metabolism during HFD feeding. Together, these data suggest that bacterial products can up-regulate IFN-I responses in the liver and that these changes are associated with intrahepatic T cell inflammation during obesity.
Loss of IFN-I signaling on intrahepatic T cells protects from metabolic disease
Because we have shown that intrahepatic CD8 + T cells have pathogenic properties in modulating glucose metabolism and that these cells are maintained by an IFN-I response, we next assessed the metabolic effects of disrupted IFN-I signaling in CD8 + T cells alone during DIO through the use of mixed bone marrow (BM) chimeric mice (29) . Irradiated recipient mice were reconstituted with BM mixtures containing 85%:15% ratios of either CD8 −/− BM + IFNR1 −/− BM (IFNR1 −/− CD8) or CD8 −/− BM + WT BM (WT CD8) and then were placed on a HFD for 16 weeks. Despite no changes in body weight, chimeric mice lacking IFNR1 on CD8 + T cells (IFNR1 −/− CD8) displayed better overall glucose tolerance, insulin sensitivity, and pyruvate tolerance compared with control counterparts (WT CD8) (Fig. 4C) . The absence of IFNR1 expression on CD8 + T cells in IFNR1 −/− CD8 mice was confirmed by flow cytometry (Fig. 4D) (Fig. 4E) . These findings pinpoint IFN-I-IFNR1 signaling in intrahepatic CD8 + T cells as an important mechanism promoting their accumulation and pathologic function in DIO.
Human fatty liver disease activity correlates with increased CD8 + T cell infiltration and IFN-I responses To assess clinical relevance of CD8
+ T cell and IFN-I responses in human livers, we measured CD8 + T cell infiltration and IFN-I-responsive proteins in human liver biopsies from patients with varying degrees of NAFLD. Histological sections were given an NAFLD activity score (NAS) ranging from low disease (NAS, 0) to advanced steatohepatitis (NAS, 8) (30), and immunohistochemical stains were evaluated by the staining intensity and tissue percentage stained. Consistent with our mouse data, we found a significant positive correlation between NAS score and IRF3 or ISG15 protein expression throughout human liver sections (Fig. 4, F and G) . In addition to IRF3 and ISG15 expression, NAS correlated with increased CD8 + infiltration in lobules and portal tracts of liver tissue (Fig. 4H) . These data suggest that human fatty livers display elevated IFN-I responses and CD8 + T cell infiltration and may serve as potential biomarkers or targets in the treatment of disease.
DISCUSSION
NAFLD and associated IR mainly have been linked to innate immunity, whereby activation of TLRs, nuclear factor B, and the inflammasome in the liver promotes disease. Our results highlight mechanisms by which DIO fuels hepatic inflammation through initiation of an IFN-I response that supports accumulation of CD8 + T cells that result in worsened overall glucose homeostasis. Hepatic CD8 + T cells likely represent a unique, highly pathogenic, tissue-specific mediator of obesityrelated glucose dysregulation. Using several methods, we identified that CD8 + T cells promote glucose dysregulation by augmenting hepatic IR and gluconeogenesis. It is likely that hepatic CD8 + T cells induce their insulin-desensitizing effects through release of IFN and TNF, which impair insulin signaling in hepatocytes. In addition, TNF has also been associated with fibrosis in NASH (9) . Although our data point to T cell-derived IFN-and TNF-mediated pathology, several studies have found that IL-17 may also be important in the pathogenesis of NAFLD (31) (32) (33) . Discrepancies surrounding the roles of IL-17 may be due to differences in the inciting model of NAFLD, lineage plasticity within T H 17 populations, or microbial variability between facilities, which dictate T H 17 responses (34) .
Although TCRV analysis of liver T cells during HFD feeding did not reveal remarkable differences, the nature of T cell responses in the liver as a result of antigen-directed or bystander responses requires further investigation. An expanding list of antigen targets is being reported for obese and IR individuals, and an autoimmune or antigen-driven component to obesity-related IR has been debated (35) .
We next identified a fundamental role for IFN-I responses in driving hepatic T cell inflammation and metabolic disease. Consistent with other recent reports, we identified enhanced hepatic gene expression of key IFN-I regulatory factors, IRF3 and IRF7, during DIO and/or NAFLD (36, 37) . Although previous studies used knockout mice to examine the role of individual IRFs associated with IFN-I pathways and their effects on glucose metabolism (36, 38, 39) , we used HFD-fed IFNR1 knockout mice to broadly eliminate IFN-I and showed that IFN-I responses, as a whole, promote obesity-related IR. A recent study reported that deletion of IFNR1 in adipocytes of HFD-fed mice resulted in worsened steatosis and metabolic parameters, whereas no differences were detected when IFNR1 was deleted in hepatocytes, intestinal epithelial cells, and myelocytes, compared with WT controls (40) . Combined with our data, these findings would still support a dominant pathogenic role for IFNR1 in lymphocytes, such as CD8 + T cells, which result in systemic IR. IFN-I-responsive CD8 + T cells appear to affect the activation status of CD4 + T cells because CD8 + IFNR1
−/− chimeric mice were found to have reduced CD4 + T cell subsets. This finding suggests that CD8 + T cells may play a fundamental role in orchestrating inflammation in fatty livers, similar to their role in VAT inflammation. Alternatively, IFN-I may impair hepatocyte insulin signaling directly (41) . Recent studies show that IFN-I can cause direct oxidative damage to hepatocytes and induces fatty acid uptake in cells, including macrophages (42, 43) .
IFN-I responses are typically induced by RNA or DNA viruses through the endosomal TLR7/TLR8/TLR9 but can also be stimulated through other TLRs, including TLR4 (23, 44) . Multiple mechanisms may contribute to the increased IFN-I response in the livers of HFDfed mice. It is possible that hepatic IFN-I responses are induced by increased bacterial products entering liver tissue because of increased intestinal permeability (45) . Here, we show that livers of HFD-fed microbiota-depleted mice have reduced IFN and CD8 + T cells, suggesting that commensal-derived ligands may be a source of antigens driving hepatic IFN-I and T cell responses. Similarly, mice treated with broad-spectrum antibiotics display decreased infiltration of intrahepatic macrophages during HFD feeding (46) . In addition to bacterial sources of antigenic stimulants, mitochondrial DNA from hepatic origin is increased in mice and patients with NASH (47), which could act as TLR9 ligands to promote IFN-I production. Other factors that might induce IFN-I responses in the liver include dietary fats, although our in vitro data for two dominant IRFs did not reach significance after addition of palmitate. Hepatocytes or IFN-I-producing intrahepatic immune cells, including plasmacytoid dendritic cells, may be sources of IFN-I production, which contribute to hepatic inflammation in obesity (48) .
Although we propose CD8 + T cells to be a dominant IFN-I-responsive cell driving our observed results, several other IFN-I-responsive immune cells may play a role. HFD-fed whole-body IFNR1 −/− mice were more protected against HFD-induced glucose dysregulation than CD8-specific IFNR1 −/− mice, suggesting that there may be other cellular subsets that require IFN-I signaling to promote disease progression. Nonetheless, we identified strong IFN-I signaling patterns within purified intrahepatic CD8 + T cells. In addition, although we identified increases in protein levels of IFN in the liver, the relative contributions of the major IFN-I effector cytokines, IFN and IFN, remain to be determined, especially because IFN can exert anti-inflammatory effects in some models of disease (49) . Moreover, long-standing IFN-I signaling is associated with immune exhaustion in models of persistent viral infection (50) . It will be interesting to assess the role of this cytokine axis in long-standing persistent metabolic disease as a mechanism of immunosuppression. Furthermore, we cannot entirely rule out a contributory role for IFN-I in modulating VAT inflammation in addition to the liver, because the etiology of NAFLD involves adipose-derived inflammatory mediators, including FFAs and cytokines (5) . A recent study reported that IRF3 expression in adipose tissue supports IR by promoting macrophage-mediated VAT inflammation and repressing browning of fat, whereas another study linked IFN-I responses in VAT to IR in a human cohort (51, 52) . However, the changes we identified during PTTs and pAkt/Akt expression in the liver do lend support to a mechanism that may affect local hepatic insulin signaling.
The potential clinical relevance of our findings was illustrated using two different human liver cohorts. Although both hepatocytes and immune cells displayed positive staining for IRF3 and ISG15 proteins in human liver sections, further investigation is warranted to delineate the relative contribution of each cell type. Furthermore, the use of IFN-I-related proteins or CD8 + T cell infiltration as possible future diagnostic markers of NAFLD or NASH disease is also an avenue of future investigation. Last, given the central role IFN-I has in mediating antiviral responses (53, 54) , additional clinical studies on the safety and efficacy of manipulating IFN-I responses for the treatment of obesity-related metabolic abnormalities are required.
Overall, our work identifies an IFN-I signaling axis as a central immunological pathway driving T cell-mediated liver inflammation during DIO. This notion identifies IFN-I as a common immunological hub shared with other liver diseases, in which IFN-I signaling plays an important role, including infectious hepatitis (55, 56) . Collectively, our findings identify that IFN-I and its responsive intrahepatic T cell subsets are important elements of metabolic syndrome pathobiology, including NAFLD and IR. Our observations provide insight into metabolic disease and propose new avenues for therapeutic strategies to combat the growing obesity epidemic and its associated metabolic abnormalities.
MATERIALS AND METHODS
Study design
The aim of this study was to investigate whether intrahepatic T cell populations promote IR and glucose intolerance during obesity and to determine factors, including IFN-I, that maintain these cells within metabolic tissues. All animal studies were performed under the approval of Animal User Protocols by the Animal Care Committee at the University Health Network (UHN). For approval of human studies, please see specific section in Materials and Methods. See Supplementary Experimental Procedures (SEPs) for full details on study design. Mice C57BL/6J (WT), C57BL/6J leptin-deficient ob/ob (ob/ob), CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ), CD8 −/− (B6.129S2-Cd8atm1Mak/J), and IFNR1 −/− (B6.129S2-Ifnar1tm1Agt/Mmjax) mice were purchased from the Jackson Laboratory. Heterozygous mice were crossed to generate C57BL/6J WT and IFNR1 −/− littermates. Mice were fed either NCD (15% kcal fat) or HFD (60% kcal fat, irradiated; Research Diets) starting at 6 weeks of age for 16 to 32 weeks (see SEPs).
Metabolic studies
Glucose and insulin testing were performed as previously described (57) . For PTTs, mice were fasted for 16 hours and then injected intraperitoneally with 1.5 g/kg (of body weight) of sodium pyruvate (Sigma) in PBS. Liver triglyceride contents were determined using a colorimetric assay (Cayman Chemical) (see SEPs).
Processing of immune cells from tissues
All tissues were weighed before processing. Immune cells were isolated from liver, VAT, and spleen, as previously described (see SEPs) (48) .
Flow cytometry
Cells were stained with commercial fluorophore-conjugated primary antibodies listed in table S1 using recommended dilutions from the supplier (BioLegend) (see SEPs).
Mixed BM chimeras
Mixed BM chimeric mice were generated using a modified protocol, as described (see SEPs) (29) .
Anti-IFNR1 treatment WT mice fed a HFD for 10 weeks were injected intraperitoneally with 400 g of either anti-IFNR1-blocking antibody (InVivoMAb, clone MAR1-5A3) or mouse IgG1 isotype control (InVivoMAb, clone MOPC-21) in 100 l of PBS once a week for 5 weeks. Metabolic tests were performed after the end of treatment course, and IFNR1 blocking was evaluated by flow cytometry.
In vivo incorporation of EdU
Mice were injected intraperitoneally with EdU (4 g/g body weight) (Invitrogen), and their livers and spleens were collected 48 hours later. Intracellular EdU was labeled with Alexa Fluor 488 in a Click-iT reaction (Invitrogen), according to the manufacturer's protocol, and mea sured by flow cytometry.
Cell transfer experiments
Hepatic immune cells or splenocytes from mice fed a HFD for 16 and 20 weeks were isolated, and CD8 + T cells were purified (>95%) using an EasySep Negative Selection kit (StemCell Technologies Inc.). CD8 −/− mice fed a HFD for 16 weeks received 5 × 10 6 hepatic or splenic CD8 + T cells intravenously in 100 l of PBS, and metabolic studies were performed 1 week after transfer.
Depletion of intestinal commensal bacteria
Mice fed a HFD for 12 weeks received a combination of ampicillin (1 g/liter; Sigma), vancomycin (0.5 g/liter; Sigma), neomycin (1 g/liter; Sigma), and metronidazole (1 g/liter; Sigma) in the drinking water for 4 weeks, as previously described (28) .
Treatment of primary hepatocytes
Primary hepatocytes were isolated from 6-to 8-week-old NCD-fed WT mice, as described (58) . Cells were then treated with recombinant IFN or TNF (20 ng/ml) (BioLegend), LPS-EK (Escherichia coli K12) (0.1 and 1 g/ml) (InvivoGen), ODN 2395 (1 and 10 g/ml) (InvivoGen), or 0.5 and 1.0 mM sodium palmitate (Sigma) for 12 or 24 hours. For pAkt/Akt Western blotting studies, cells were treated with 100 nM insulin (Eli Lilly) for 15 min (see SEPs).
Western blotting
Western blotting was performed as previously described (see SEPs) (57) .
RNA isolation and quantitative real-time polymerase chain reaction
Primer sets are listed in table S2. Changes in gene expression were calculated by the 2 −CT method using mean cycle threshold (C T ) values as described (57) . Expression of glyceraldehyde-3-phosphate dehydrogenase did not change between groups, and results are shown as fold changes relative to the control group (see SEPs).
Histology and human liver biopsies
For human studies, a cohort of 19 human liver biopsies taken from patients with varying degrees of NAFLD and NASH were sectioned and 18 were stained for H&E, anti-human CD8 (Abcam, clone 144B), and anti-human ISG15 (Abcam, clone EPR3445) and 19 were stained for anti-human IRF3 (Abcam, clone EPR2418Y) that were detected using an ImmPRESS kit (Vector Laboratories), followed by chromogen exposure as described (25) . All histochemical and immunohistochemical stains were performed by the UHN Pathology Research Program laboratories at the UHN. All human specimens were obtained with study approval by the Research Ethics Board for Human Subjects at the UHN (see SEPs).
Isolation of human intrahepatic mononuclear cells
Liver-associated mononuclear cells were isolated from the livers of cadaveric donors (n = 30) at the Mid-America Transplant Services for organs assigned for transplant at the Saint Louis University Hospital or Barnes-Jewish Hospital Abdominal Transplant Programs. The patient cohort consisted of 18 males and 12 females, with an average age of 43.57. HbA1c was measured and available for 21 patients, and analysis of intrahepatic immune cell subsets was performed by flow cytometry, as described (20, 59) . The study was approved by Saint Louis University, and informed consent was provided by next of kin (see SEPs).
Statistical analysis
Statistical significance between two means was assessed with an unpaired, two-sided Student's t test using GraphPad Prism 5 (GraphPad Software Inc.). In the figure legends, where specified, the number of biological experiments is listed as the n value. All data represent means ± SEM. Spearman rank correlation coefficient tests were performed to analyze correlative studies. Statistical significance is denoted by *P < 0.05, **P < 0.01, and ***P < 0.001. Statistical significance was set at P < 0.05.
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